Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity rate is linked to both late-stage diagnosis and unresponsiveness to conventional...
Published in: | International Journal of Molecular Sciences |
---|---|
Main Authors: | , , , , |
Format: | Text |
Language: | English |
Published: |
MDPI
2020
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352617/ http://www.ncbi.nlm.nih.gov/pubmed/32560253 https://doi.org/10.3390/ijms21124292 |
id |
ftpubmed:oai:pubmedcentral.nih.gov:7352617 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:7352617 2023-05-15T16:29:20+02:00 Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma Renaud, Sarah Lefebvre, Anthony Mordon, Serge Moralès, Olivier Delhem, Nadira 2020-06-16 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352617/ http://www.ncbi.nlm.nih.gov/pubmed/32560253 https://doi.org/10.3390/ijms21124292 en eng MDPI http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352617/ http://www.ncbi.nlm.nih.gov/pubmed/32560253 http://dx.doi.org/10.3390/ijms21124292 © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). CC-BY Int J Mol Sci Review Text 2020 ftpubmed https://doi.org/10.3390/ijms21124292 2020-07-26T00:23:53Z Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity rate is linked to both late-stage diagnosis and unresponsiveness to conventional anti-cancer treatments. Multiple aetiological factors have been described including environmental factors, genetics, and viral factors (Epstein Barr Virus, EBV), making NPC treatment that much more complex. The most common forms of NPCs are those that originate from the epithelial tissue lining the nasopharynx and are often linked to EBV infection. Indeed, they represent 75–95% of NPCs in the low-risk populations and almost 100% of NPCs in high-risk populations. Although conventional surgery has been improved with nasopharyngectomy’s being carried out using more sophisticated surgical equipment for better tumour resection, recent findings in the tumour microenvironment have led to novel treatment options including immunotherapies and photodynamic therapy, able to target the tumour and improve the immune system. This review provides an update on the disease’s aetiology and the future of NPC treatments with a focus on therapies activating T cell immunity. Text Greenland PubMed Central (PMC) Greenland International Journal of Molecular Sciences 21 12 4292 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Review |
spellingShingle |
Review Renaud, Sarah Lefebvre, Anthony Mordon, Serge Moralès, Olivier Delhem, Nadira Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
topic_facet |
Review |
description |
Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity rate is linked to both late-stage diagnosis and unresponsiveness to conventional anti-cancer treatments. Multiple aetiological factors have been described including environmental factors, genetics, and viral factors (Epstein Barr Virus, EBV), making NPC treatment that much more complex. The most common forms of NPCs are those that originate from the epithelial tissue lining the nasopharynx and are often linked to EBV infection. Indeed, they represent 75–95% of NPCs in the low-risk populations and almost 100% of NPCs in high-risk populations. Although conventional surgery has been improved with nasopharyngectomy’s being carried out using more sophisticated surgical equipment for better tumour resection, recent findings in the tumour microenvironment have led to novel treatment options including immunotherapies and photodynamic therapy, able to target the tumour and improve the immune system. This review provides an update on the disease’s aetiology and the future of NPC treatments with a focus on therapies activating T cell immunity. |
format |
Text |
author |
Renaud, Sarah Lefebvre, Anthony Mordon, Serge Moralès, Olivier Delhem, Nadira |
author_facet |
Renaud, Sarah Lefebvre, Anthony Mordon, Serge Moralès, Olivier Delhem, Nadira |
author_sort |
Renaud, Sarah |
title |
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
title_short |
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
title_full |
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
title_fullStr |
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
title_full_unstemmed |
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
title_sort |
novel therapies boosting t cell immunity in epstein barr virus-associated nasopharyngeal carcinoma |
publisher |
MDPI |
publishDate |
2020 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352617/ http://www.ncbi.nlm.nih.gov/pubmed/32560253 https://doi.org/10.3390/ijms21124292 |
geographic |
Greenland |
geographic_facet |
Greenland |
genre |
Greenland |
genre_facet |
Greenland |
op_source |
Int J Mol Sci |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352617/ http://www.ncbi.nlm.nih.gov/pubmed/32560253 http://dx.doi.org/10.3390/ijms21124292 |
op_rights |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
op_rightsnorm |
CC-BY |
op_doi |
https://doi.org/10.3390/ijms21124292 |
container_title |
International Journal of Molecular Sciences |
container_volume |
21 |
container_issue |
12 |
container_start_page |
4292 |
_version_ |
1766019037417963520 |